Kinetic disposition of ursolic acid in rats

Benznidazole and nifurtimox are two drugs that are used to treat trypanosomiasis. Ursolic acid (UA) reportedly acts against trypomastigotes and intracellular amastigotes of Trypanosoma cruzi. Accordingly, it is expected to have therapeutic benefits in the treatment of trypanosomiasis. Therapeutic application of a compound requires the investigation of its pharmacokinetic properties in order to obtain relevant information to design the in vivo assays and dose regimen. Regarding this, the current study aimed to evaluate the pharmacokinetic profile of UA administered to rats at different doses and routes (i.e., 1 mg/kg intravenously and 20 and 50 mg/kg orally). According to the results, the oral bioavailability was significantly different between the two groups that orally received the UA doses of 20 mg/kg (2.8%) and 50 mg/kg (1.55 %). The result suggests the interference of the poor aqueous solubility of UA on its absorption process. The pharmacokinetic parameters related to the distribution and elimination were similar. Accordingly, it can be concluded that at this dose range, there is no saturation in this process rendering a linear the kinetics. The pharmacokinetic properties of UA were observed in this study indicated that the improvement of water solubility in this medicine through pharmacotechnical resources would be a great utility for its oral bioavailability and development of a product with the potential therapeutic application. The oral administration of this new pharmaceutical formulation should be investigated in future studies.

[1]  I. Androulakis,et al.  Pharmacokinetics and Pharmacodynamics of the Triterpenoid Ursolic Acid in Regulating the Antioxidant, Anti-inflammatory, and Epigenetic Gene Responses in Rat Leukocytes. , 2017, Molecular pharmaceutics.

[2]  J. Urbina.  Recent Clinical Trials for the Etiological Treatment of Chronic Chagas Disease: Advances, Challenges and Perspectives , 2015, The Journal of eukaryotic microbiology.

[3]  Chagas disease in Latin America: an epidemiological update based on 2010 estimates. , 2015, Releve epidemiologique hebdomadaire.

[4]  E. Padilha,et al.  Pharmacokinetic profile of a new diclofenac prodrug without gastroulcerogenic effect. , 2013, Drug metabolism letters.

[5]  Lei Yang,et al.  Physicochemical properties and oral bioavailability of ursolic acid nanoparticles using supercritical anti-solvent (SAS) process. , 2012, Food chemistry.

[6]  Zilin Chen,et al.  Development of a liquid chromatography–mass spectrometry method for the determination of ursolic acid in rat plasma and tissue: Application to the pharmacokinetic and tissue distribution study , 2011, Analytical and bioanalytical chemistry.

[7]  Y. Carlier.  Globalization of Chagas disease (American trypanosomiasis): the situation in Europe and Belgium. , 2011, Bulletin et memoires de l'Academie royale de medecine de Belgique.

[8]  S. Albuquerque,et al.  Trypanocidal activity and acute toxicity assessment of triterpene acids , 2010, Parasitology Research.

[9]  Y. Ikeda,et al.  Ursolic acid: an anti- and pro-inflammatory triterpenoid. , 2008, Molecular nutrition & food research.

[10]  Seshadri Neervannan,et al.  Preclinical formulations for discovery and toxicology: physicochemical challenges , 2006, Expert opinion on drug metabolism & toxicology.

[11]  F. Dosio,et al.  Stealth liposomes: review of the basic science, rationale, and clinical applications, existing and potential , 2006, International journal of nanomedicine.

[12]  B. Aggarwal,et al.  Role of chemopreventive agents in cancer therapy. , 2004, Cancer letters.

[13]  A. Vachálková,et al.  Pentacyclic triterpenoic acids: new chemoprotective compounds. Minireview. , 2004, Neoplasma.

[14]  R Panchagnula,et al.  Biopharmaceutics and pharmacokinetics in drug research. , 2000, International journal of pharmaceutics.